Asia Pacific Dementia Treatment Market

Asia Pacific Dementia Treatment Market Size, Share & Trends Analysis Report By Type, By Dementia Drugs Route of Administration (Oral, Transdermal Patch, and Injectable), By Dementia Drugs Distribution Channel, By Indication, By Country and Growth Forecast, 2024 - 2031

Report Id: KBV-23205 Publication Date: June-2024 Number of Pages: 174
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Asia Pacific Dementia Treatment Market would witness market growth of 8.0% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $2,139.1 million by 2031. The Japan market is registering a CAGR of 7.3% during (2024 - 2031). Additionally, The India market would capture a CAGR of 8.7% during (2024 - 2031).

Asia Pacific Dementia Treatment Market

The increasing investment in healthcare infrastructure globally is facilitating the growth of the dementia treatment market. In order to accommodate the increasing number of dementia patients, governments and private entities are making investments in the construction as well as modernization of healthcare facilities. This encompasses the establishment of innovative diagnostic tools and therapeutic modalities in specialized memory clinics and dementia care centers. Such investments are crucial in enhancing the early detection and management of dementia, improving patient outcomes and quality of life.

Pharmacological treatments remain a cornerstone of dementia management, with ongoing research focused on developing new and more effective medications. Current treatments primarily aim to manage symptoms and improve cognitive function. Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are commonly prescribed to improve cognitive symptoms in mild to moderate Alzheimer’s disease. NMDA receptor antagonists, like memantine, treat moderate to severe cases.

In India, the demand for dementia treatment is growing due to the increasing prevalence of dementia and the country’s aging population. According to the National Library of Medicine, approximately 8.8 million people in India were living with dementia in 2023, a number expected to increase significantly in the coming decades. The Indian government has been working to improve dementia care through initiatives like the National Programme for Health Care of the Elderly (NPHCE), which includes provisions for dementia care and support. Increased awareness, early diagnosis efforts, and investments in healthcare infrastructure drive the demand for dementia treatments in India. Therefore, the demand for dementia treatments will rise significantly in this region in the coming years.

Free Valuable Insights: The Global Dementia Treatment Market is Predict to reach USD 29.2 Billion by 2031, at a CAGR of 7.4%

Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Eisai Co., Ltd.
  • Eli Lilly And Company
  • F.Hoffmann-La Roche Ltd.
  • Biogen, Inc.
  • AbbVie, Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline PLC (GSK)
  • Cipla Limited

Asia Pacific Dementia Treatment Market Report Segmentation

By Type

  • Diagnosis
    • Imaging Techniques
    • Cognitive Assessment Tools
    • Genetic Testing
    • Biomarker Analysis
    • Others
  • Drugs
    • Cholinesterase Inhibitors
    • NMDA Receptor Antagonist
    • MAO Inhibitors
    • Combination Drug
    • Others

By Dementia Drugs Route of Administration

  • Oral
  • Transdermal Patch
  • Injectable

By Dementia Drugs Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Indication

  • Alzheimer’s Disease Dementia
  • Vascular Dementia
  • Lewy Body Dementia
  • Frontotemporal Dementia (FTD)
  • Parkinson Disease Dementia
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo